Related Experiment Video
Updated: Jun 30, 2025
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
C-type lectin 2D (CLEC2D) is upregulated in clear cell renal cell carcinoma (ccRCC) tissues and predicts poor
Huibing Li1, Pengyi Zheng1, Zhijun Li1
1Department of Urology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China.
Abstract:
Clear cell renal cell carcinoma (ccRCC) is known as the most common type of renal cancer. Recently, a series of advances have been made in targeted therapy for ccRCC. To combat this highly metastatic tumor, novel therapeutic targets still need to be developed. C-type lectins (CLECs) contain a characteristic C-type lectin-like domain and affect several physiological functions. The effects of C-type lectin 2D (CLEC2D) on cancer progression have been revealed in several types of cancers; however, its expression in ccRCC tissues, and the possible effects on the progression and metastasis of ccRCC, are still unclear. Herein, we found the high mRNA and protein levels of CLEC2D in ccRCC tissues. We further found that CLEC2D expression was correlated with the prognosis of ccRCC patients and correlated with the tumor size (p = 0.019*) of patients. In addition, CLEC2D affected tumor immune infiltration, confirmed by the further analysis. CLEC2D knockdown suppressed the proliferation of ccRCC cells in vitro and restrained ccRCC tumor growth and immune infiltration in mice. Therefore, we believe that CLEC2D has the potential to serve as a promising ccRCC therapeutic target.
Insights
High levels of C-type lectin 2D (CLEC2D) correlate with poor prognosis in clear cell renal cell carcinoma (ccRCC). Targeting CLEC2D may offer a new therapeutic strategy for this common kidney cancer.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer, with ongoing research into targeted therapies.
- Novel therapeutic targets are crucial for managing ccRCC metastasis.
- C-type lectin 2D (CLEC2D) function in ccRCC remains largely uncharacterized.
Purpose of the Study:
- To investigate the expression and role of CLEC2D in ccRCC.
- To determine if CLEC2D is a potential therapeutic target for ccRCC.
Main Methods:
- Analysis of CLEC2D mRNA and protein levels in ccRCC tissues.
- Correlation analysis of CLEC2D expression with patient prognosis and tumor size.
- Assessment of CLEC2D's impact on tumor immune infiltration.
- In vitro ccRCC cell proliferation assays.
- In vivo mouse models to evaluate tumor growth and immune infiltration after CLEC2D knockdown.
Main Results:
- CLEC2D exhibited high mRNA and protein expression in ccRCC tissues.
- CLEC2D expression correlated significantly with poorer patient prognosis and larger tumor size.
- CLEC2D influenced tumor immune infiltration.
- Knockdown of CLEC2D reduced ccRCC cell proliferation in vitro and suppressed tumor growth and immune infiltration in vivo.
Conclusions:
- CLEC2D is upregulated in ccRCC and associated with adverse clinical outcomes.
- CLEC2D plays a role in ccRCC progression and immune evasion.
- CLEC2D represents a promising therapeutic target for ccRCC treatment.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
14:14Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Related Concept Videos
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
01:25Selectins